BR9915940A - Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 - Google Patents
Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53Info
- Publication number
- BR9915940A BR9915940A BR9915940-6A BR9915940A BR9915940A BR 9915940 A BR9915940 A BR 9915940A BR 9915940 A BR9915940 A BR 9915940A BR 9915940 A BR9915940 A BR 9915940A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- methods
- family
- restore
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: <B>"MéTODOS E COMPOSIçõES PARA RESTAURAR A ESTABILIDADE CONFORMACIONAL DE UMA PROTEìNA DA FAMìLIA p53"<D>. A invenção situa-se no campo do tratamento do câncer. Em particular, a presente invenção proporciona compostos farmacêuticos capazes de interação com formas mutantes e não-mutantes de proteínas reguladoras relacionadas com câncer tal que a proteína mutante recupera a capacidade de interagir apropriadamente com outras macromoléculas, restaurando ou estabilizando por esse meio toda ou uma porção da sua atividade do tipo selvagem. As proteínas reguladoras incluem membros da família de proteínas p53 tais como, por exemplo, p53, p63 e p73. Os compostos da invenção são úteis para o tratamento do câncer. Métodos para triar tais compostos farmacológicos são também fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11054298P | 1998-12-02 | 1998-12-02 | |
PCT/IB1999/001916 WO2000032175A2 (en) | 1998-12-02 | 1999-12-01 | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9915940A true BR9915940A (pt) | 2001-09-11 |
Family
ID=22333594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9915940-6A BR9915940A (pt) | 1998-12-02 | 1999-12-01 | Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20020048271A1 (pt) |
EP (1) | EP1137418A2 (pt) |
JP (2) | JP2002531396A (pt) |
KR (1) | KR20010086073A (pt) |
CN (1) | CN1329493A (pt) |
AP (1) | AP2001002153A0 (pt) |
AU (1) | AU1290700A (pt) |
BG (1) | BG105599A (pt) |
BR (1) | BR9915940A (pt) |
CA (1) | CA2350597A1 (pt) |
EA (1) | EA003326B1 (pt) |
EE (1) | EE200100302A (pt) |
HK (1) | HK1041644A1 (pt) |
HR (1) | HRP20010414A2 (pt) |
HU (1) | HUP0201215A2 (pt) |
ID (1) | ID29061A (pt) |
IL (1) | IL143094A0 (pt) |
IS (1) | IS5943A (pt) |
NO (1) | NO20012737L (pt) |
OA (1) | OA11722A (pt) |
PL (1) | PL348310A1 (pt) |
TR (1) | TR200101549T2 (pt) |
WO (1) | WO2000032175A2 (pt) |
YU (1) | YU35401A (pt) |
ZA (1) | ZA200104210B (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US20030022243A1 (en) * | 2001-06-20 | 2003-01-30 | Les Kondejewski | Protein aggregation assays and uses thereof |
JP2005510460A (ja) * | 2001-08-10 | 2005-04-21 | メディカル リサーチ カウンシル | 分子 |
AU2003298512A1 (en) * | 2002-05-06 | 2004-05-04 | Colorado State University Research Foundation | Genotoxicity analysis |
AU2003258662A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
ES2272911T3 (es) * | 2003-04-25 | 2007-05-01 | Neurofit Sas | Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns. |
US6970791B1 (en) * | 2003-05-23 | 2005-11-29 | Verachem, Llc | Tailored user interfaces for molecular modeling |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
JP5129957B2 (ja) * | 2003-07-03 | 2013-01-30 | ミリアド ジェネティクス, インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての4−アリールアミノ−キナゾリン |
WO2005051915A1 (en) * | 2003-11-21 | 2005-06-09 | Merck & Co., Inc. | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
CN1909927A (zh) * | 2003-12-24 | 2007-02-07 | 株式会社洛科摩基因 | 抑制癌的方法 |
WO2005061007A1 (ja) * | 2003-12-24 | 2005-07-07 | St. Marianna University School Of Medicine | 癌の抑制方法 |
WO2005120509A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
CA2615373A1 (en) * | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
WO2007107545A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
NZ546477A (en) * | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
MY162844A (en) * | 2006-07-10 | 2017-07-31 | The Trustee Of Columbia Univ In The City Of New York | Anti-cocaine compositions and treatment |
WO2008155441A1 (en) | 2007-06-20 | 2008-12-24 | Marikki Laiho | Activators and therapeutic applications thereof |
AU2008275025C1 (en) * | 2007-07-10 | 2016-01-28 | The Regents Of The University Of Michigan | Thermostabilization of proteins |
ES2534899T3 (es) | 2007-08-06 | 2015-04-30 | Janssen Pharmaceutica, N.V. | Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53 |
EA021883B1 (ru) | 2009-02-04 | 2015-09-30 | Янссен Фармацевтика Нв | Производные индола в качестве противораковых агентов |
WO2011127406A2 (en) * | 2010-04-09 | 2011-10-13 | The Brigham And Women's Hospital, Inc. | Acridines as inhibitors of haspin and dyrk kinases |
WO2012154879A2 (en) | 2011-05-09 | 2012-11-15 | Van Andel Research Institute | Autophagy inhibitors |
WO2013043744A2 (en) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
CN102660257B (zh) * | 2012-05-22 | 2013-11-27 | 南京邮电大学 | 吩噻嗪基喹唑啉类荧光离子探针及其应用 |
EP3201234B1 (en) * | 2014-09-30 | 2018-11-07 | Diadem S.r.l. | Antibody binding a linear epitope of human p53 and diagnostic applications thereof |
CN105399670B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途 |
CN105399671B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
CN105418501B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
EP3411390A1 (en) | 2016-02-04 | 2018-12-12 | Yeda Research and Development Co. Ltd | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
CN109069481A (zh) | 2016-02-19 | 2018-12-21 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
CN109694358B (zh) * | 2019-01-23 | 2022-02-08 | 广西师范大学 | 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用 |
WO2021061643A1 (en) * | 2019-09-23 | 2021-04-01 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
US20210405056A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Methods for detecting mutant p53 function |
KR20230028484A (ko) | 2020-06-24 | 2023-02-28 | 피엠브이 파마슈티컬스 인코포레이티드 | 암의 치료를 위한 병용 요법 |
GB202111035D0 (en) * | 2021-07-30 | 2021-09-15 | Vestlandets Innovasjonsselskap As | Therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
DK0746613T3 (da) * | 1994-03-08 | 2006-09-25 | Sloan Kettering Inst Cancer | Rekombinante humaniserede antistoffer mod FB5 |
AU708829B2 (en) * | 1994-12-13 | 1999-08-12 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US6270954B1 (en) * | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
EP0959877A4 (en) * | 1996-04-10 | 2000-08-23 | Univ California | CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS |
DE19624154A1 (de) * | 1996-06-18 | 1998-01-08 | Hoechst Ag | Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung |
US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
CN1228772A (zh) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 杂环金属蛋白酶抑制剂 |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
US6387903B1 (en) * | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
FI105554B (fi) * | 1998-05-13 | 2000-09-15 | Galilaeus Oy | Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit |
US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
AU5197599A (en) * | 1998-08-12 | 2000-03-06 | Daiichi Pure Chemicals Co., Ltd. | Fluorescent labelling reagents |
SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
AU4564200A (en) * | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6406699B1 (en) * | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
WO2001028550A1 (en) * | 1999-10-15 | 2001-04-26 | Mayo Foundation For Medical Education And Research | Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia |
US6372785B1 (en) * | 2000-05-04 | 2002-04-16 | Keith Chan, President Globoasia, Llc | Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon |
US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6391916B1 (en) * | 2000-07-21 | 2002-05-21 | The Hong Kong University Of Science And Technology | Enediyne derivatives |
-
1999
- 1999-12-01 ID IDW00200101178A patent/ID29061A/id unknown
- 1999-12-01 AU AU12907/00A patent/AU1290700A/en not_active Abandoned
- 1999-12-01 OA OA1200100136A patent/OA11722A/en unknown
- 1999-12-01 KR KR1020017006830A patent/KR20010086073A/ko not_active Application Discontinuation
- 1999-12-01 JP JP2000584871A patent/JP2002531396A/ja active Pending
- 1999-12-01 CN CN99814010A patent/CN1329493A/zh active Pending
- 1999-12-01 EE EEP200100302A patent/EE200100302A/xx unknown
- 1999-12-01 BR BR9915940-6A patent/BR9915940A/pt not_active IP Right Cessation
- 1999-12-01 YU YU35401A patent/YU35401A/sh unknown
- 1999-12-01 CA CA002350597A patent/CA2350597A1/en not_active Abandoned
- 1999-12-01 HU HU0201215A patent/HUP0201215A2/hu unknown
- 1999-12-01 WO PCT/IB1999/001916 patent/WO2000032175A2/en not_active Application Discontinuation
- 1999-12-01 PL PL99348310A patent/PL348310A1/xx unknown
- 1999-12-01 AP APAP/P/2001/002153A patent/AP2001002153A0/en unknown
- 1999-12-01 TR TR2001/01549T patent/TR200101549T2/xx unknown
- 1999-12-01 EP EP99956270A patent/EP1137418A2/en not_active Withdrawn
- 1999-12-01 IL IL14309499A patent/IL143094A0/xx unknown
- 1999-12-01 EA EA200100502A patent/EA003326B1/ru not_active IP Right Cessation
-
2001
- 2001-05-15 IS IS5943A patent/IS5943A/is unknown
- 2001-05-23 US US09/863,976 patent/US20020048271A1/en not_active Abandoned
- 2001-05-23 ZA ZA200104210A patent/ZA200104210B/en unknown
- 2001-05-29 HR HR20010414A patent/HRP20010414A2/hr not_active Application Discontinuation
- 2001-06-01 NO NO20012737A patent/NO20012737L/no not_active Application Discontinuation
- 2001-06-14 BG BG105599A patent/BG105599A/xx unknown
-
2002
- 2002-05-04 HK HK02103378.4A patent/HK1041644A1/zh unknown
-
2006
- 2006-01-06 JP JP2006001475A patent/JP2006166920A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000032175A2 (en) | 2000-06-08 |
WO2000032175A3 (en) | 2000-08-03 |
EE200100302A (et) | 2002-08-15 |
NO20012737D0 (no) | 2001-06-01 |
OA11722A (en) | 2005-01-25 |
HK1041644A1 (zh) | 2002-07-19 |
ZA200104210B (en) | 2003-02-24 |
IL143094A0 (en) | 2002-04-21 |
CN1329493A (zh) | 2002-01-02 |
IS5943A (is) | 2001-05-15 |
EA200100502A1 (ru) | 2001-12-24 |
KR20010086073A (ko) | 2001-09-07 |
EP1137418A2 (en) | 2001-10-04 |
ID29061A (id) | 2001-07-26 |
US20020048271A1 (en) | 2002-04-25 |
NO20012737L (no) | 2001-07-09 |
JP2002531396A (ja) | 2002-09-24 |
AP2001002153A0 (en) | 2001-06-30 |
HRP20010414A2 (en) | 2002-06-30 |
JP2006166920A (ja) | 2006-06-29 |
TR200101549T2 (tr) | 2001-11-21 |
YU35401A (sh) | 2005-07-19 |
EA003326B1 (ru) | 2003-04-24 |
PL348310A1 (en) | 2002-05-20 |
AU1290700A (en) | 2000-06-19 |
HUP0201215A2 (en) | 2002-08-28 |
CA2350597A1 (en) | 2000-06-08 |
BG105599A (en) | 2002-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9915940A (pt) | Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 | |
DK0600866T3 (da) | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler | |
ES2146774T3 (es) | Polimeros de ioneno que contienen aniones biologicamente activos. | |
BR9814375A (pt) | Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas | |
BR9711098B1 (pt) | compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas. | |
DE3783282D1 (de) | Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen. | |
DE69202207D1 (de) | Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan. | |
NO20014415D0 (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
EA199901031A1 (ru) | Производные бензимидазола | |
SE9802729D0 (sv) | Novel Compounds | |
BR9713338A (pt) | Benzonaftiridinas como terapêuticos brÈnquicos. | |
BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
DE58904683D1 (de) | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. | |
FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
DE69919379D1 (de) | Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen | |
ES2109260T3 (es) | Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. | |
BR9913072A (pt) | Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia | |
ATE385517T1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
BR0110077A (pt) | Compostos e composições antipicornavirais, seus usos farmacêuticos, e materiais para a sua sìntese | |
ATE213233T1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
DE69333962D1 (de) | Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen | |
NO20001758L (no) | FremgangsmÕter og blandinger for behandling av leddgikt | |
BR0309412A (pt) | Indol-2-onas como inibidores seletivos da ciclooxigenase-2 | |
ATE8880T1 (de) | Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007. |